Medicare AdvantageCoverageMedium impact
MA07.041c, Drug-Eluting Beads and Bland Embolization for the Treatment of Hepatic Malignancies
Independence Blue Cross·Radiology, Oncology, Gastroenterology·Pharmacy
Effective date
Oct 29, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA07.041c regarding drug-eluting beads and bland embolization for hepatic malignancies has been reissued with revisions. This policy affects interventional radiology procedures for liver cancer treatment and will take effect October 29, 2025.
Action Required
Before October 29, 2025: Billing team should review the complete policy document at the provided URL to understand specific coverage criteria and documentation requirements for drug-eluting beads and bland embolization procedures for hepatic malignancies. Update prior authorization protocols and billing guidelines accordingly for Medicare Advantage plans.